GRP
ADAP

Global Retirement Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Global Retirement Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.23K Hold
6,000
– – ﹤0.01% 2889
2024
Q3 		$5.7K Hold
6,000
– – ﹤0.01% 2512
2024
Q2 		$5.85K Hold
6,000
– – ﹤0.01% 2547
2024
Q1 		$9.48K Hold
6,000
– – ﹤0.01% 2152
2023
Q4 		$4.26K Hold
6,000
– – ﹤0.01% 2389
2023
Q3 		$4.37K Hold
6,000
– – ﹤0.01% 2239
2023
Q2 		$5.55K Hold
6,000
– – ﹤0.01% 2162
2023
Q1 		$8.4K Buy
+6,000
New +$9.29K ﹤0.01% 1984

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Global Retirement Partners's ADAP Position: Q4 2024 in Review

Global Retirement Partners held its Adaptimmune Therapeutics (ADAP) position steady in Q4 2024 at 6,000 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2889.

Global Retirement Partners first reported a position in ADAP in Q1 2023 and has held it in 8 quarters since. The position peaked at $9.48K in Q1 2024. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • Global Retirement Partners held 6,000 shares of Adaptimmune Therapeutics worth $3.23K as of Q4 2024.
  • Global Retirement Partners left its Adaptimmune Therapeutics share count unchanged in Q4 2024.
  • Adaptimmune Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2024, its #2889 holding.
  • Global Retirement Partners first reported a position in Adaptimmune Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • Global Retirement Partners's Adaptimmune Therapeutics position peaked at $9.48K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Global Retirement Partners's 13F filing for Q4 2024, filed 31 Jan 2025.